Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Drug manufacturer Novo Nordisk announced a new experimental weight-loss pill to treat obesity in development called amycretin ...

The drug, called amycretin, helped volunteer patients lose a whopping 13 percent of their body weight over just 12 weeks. That means the new pill may be even more effective than the company's ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

The Danish pharma has previously said it expects CagriSema and amycretin to achieve better weight loss results than Wegovy. Lilly is also developing the GIP/GLP-1/glucagon receptor agonist ...

Why? Results from a Phase I trial of a new amycretin pill indicate that a highly effective and less intrusive weight loss drug is on the way, providing an alternative to the injection-based Ozempic.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

But fear not, Novo Nordisk is now developing a possibly cheaper weight loss medication, a pill called amycretin, which has indications that it could be even more effective in helping people lose ...

Novo has oral weight-loss pills in its pipeline, such as Rybelsus (already approved to treat type 2 diabetes) and Amycretin, that it’s working to bring to market. “The next leg of competition ...

The new pill, amycretin, mimics the weight-loss capabilities of Ozempic but is delivered in a pill rather than an injection.